12.70
-0.15 (-1.17%)
| Previous Close | 12.85 |
| Open | 12.73 |
| Volume | 168,688 |
| Avg. Volume (3M) | 213,452 |
| Market Cap | 502,915,680 |
| Price / Earnings (Forward) | 31.55 |
| Price / Sales | 0.630 |
| Price / Book | 1.17 |
| 52 Weeks Range | |
| Earnings Date | 24 Feb 2026 |
| Profit Margin | -17.78% |
| Operating Margin (TTM) | -17.64% |
| Diluted EPS (TTM) | -3.70 |
| Quarterly Revenue Growth (YOY) | 2.70% |
| Total Debt/Equity (MRQ) | 42.06% |
| Current Ratio (MRQ) | 2.71 |
| Operating Cash Flow (TTM) | 25.99 M |
| Levered Free Cash Flow (TTM) | 67.13 M |
| Return on Assets (TTM) | -5.00% |
| Return on Equity (TTM) | -27.82% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Mixed | |
| Stock | Orthofix Medical Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | -4.0 |
| Average | -0.38 |
|
Orthofix Medical Inc. is a medical device company delivering orthopedic and spine solutions to healthcare providers. The company has two main segments: global spine, including bone growth and healing therapies, spinal implants, and regenerative tissue products; and global orthopedics, providing products used in fracture repair, deformity correction, and bone reconstruction procedures. The majority of the company's sales come from the global spine segment in the United States. Orthofix distributes its products throughout North America, Europe, and several countries across the globe. The company provides solutions to hospitals, physicians, other healthcare providers, and patients. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Value |
| % Held by Insiders | 2.79% |
| % Held by Institutions | 87.90% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Ayal Capital Advisors Ltd | 30 Sep 2025 | 829,900 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 18.00 (Barrington Research, 41.73%) | Buy |
| Median | 16.00 (25.98%) | |
| Low | 14.00 (TD Cowen, 10.24%) | Hold |
| Average | 16.00 (25.98%) | |
| Total | 1 Buy, 1 Hold | |
| Avg. Price @ Call | 13.42 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Barrington Research | 17 Feb 2026 | 18.00 (41.73%) | Buy | 13.50 |
| TD Cowen | 27 Jan 2026 | 14.00 (10.24%) | Hold | 13.33 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 03 Feb 2026 | Announcement | Orthofix to Report Fourth Quarter and Full-Year 2025 Financial Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |